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Highfdose chemotherapy and/or radiation therapy followed by autologous hematofpoietic stemfcell transplantation (HSCT) 
has evolved as a treatment option for a variety of maf
lignancies.1f4 This form of transplantation entails the 
infusion of a patient’s own hematopoietic stem cells, 
after being harvested and preserved, to reestablish hef
matopoiesis and rescue the patient from the otherwise 
lethal toxicity of chemotherapy and/or radiation therf
apy. Peripheral blood stem cells (PBSCs) have replaced 
bone marrow (BM)fderived cells in transplants as the 
source of stem cells due to many advantages, includf
ing less invasive methods of cell collection, reduced 
tumor contamination, a higher number of harvested 
stem cells and more rapid recovery of neutrophils and 
platelets and thus engraftment.5 Because PBSCs exf
ist in the circulation in very small numbers, they must 
be mobilized from the BM into the circulation by a 
mobilizing agent(s) prior to being collected by apherf
esis.5,6 The adequacy of the number of PBSCs mobif
lized is assessed by determining the number of cells 
that have the CD34 antigen marker and the CD34+ 
cell dose/kg has proven to be a useful value. In general, 
patients who receive more than 2×106 CD34+ cells/
kg have rapid and sustained hematopoietic recovery.6 
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high-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation is an impor-
tant treatment option for a variety of malignancies. peripheral blood stem cells (pbscs) have replaced 
bone marrow-derived cells as source of stem cells in transplants, and the success of a transplant depends 
highly on the number of pbscs mobilized, collected and eventually infused. nevertheless, a good per-
centage of patients fail to mobilize stem cells when growth factors alone or in combination with che-
motherapy are used. recently, plerixafor has been approved as a novel agent to mobilize stem cells in 
multiple myeloma and lymphoma patients. data on the efficacy and safety of plerixafor in solid tumors 
is lacking. We report the successful stem cell mobilization and transplantation for a patient with a germ 
cell tumor using plerixafor.
Nevertheless, approximately 10% to 30% of patients 
are unable to collect this number to support HSCT 
when mobilized with hematopoietic growth factors 
alone or in combination with chemotherapy.7,8 
Recently, plerixafor (AMD3100, Mozobil; 
Genzyme, USA) has emerged as a novel mobilizing 
agent and showed efficacy in two phase III studies 
in mobilizing patients with nonfHodgkin lymphoma 
(NHL) and multiple myeloma (MM).8,9 Accordingly, 
plerixafor has been approved by the United States Food 
and Drug Administration (FDA) and the European 
Medicines Agency to enhance mobilization of stem 
cells to the bloodstream, in combination with granulof
cyte colony stimulating factor (GfCSF), for collection 
and subsequent autologous transplantation in patients 
with NHL and MM. Unfortunately, information on 
the safety and efficacy of plerixafor in patients with 
solid tumors is lacking. We report our experience at 
the King Hussein Cancer Center (KHCC) with using 
plerixafor to mobilize PBSCs in a patient with germ 
cell tumor who failed mobilization with GfCSF. 
CASE
A 47fyearfold male was diagnosed with a mixed germ 
cell tumor in 2006 for which he underwent orchiectof
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my followed by four courses of bleomycin plus etoposide 
plus cisplatin (BEP). The patient did well until February 
2008, when he had relapse, so he received four cycles of 
vinblastin plus ifosfamide plus cisplatin (VeIP). One 
year later, his disease progressed and he was given four 
cycles of paclitaxel plus ifosfamide plus cisplatin (TIP) 
and referred for HSCT.
Initially, PBSC mobilization was tried with GfCSF 
at 5 mcg/kg every 12 hrs for five days. On day five of 
mobilization, the white blood cell (WBC) count was 
23.3×106/mL and the absolute circulating CD34+ 
cells count was 9.3 per µL, so the collection was not 
performed. Another attempt was made after five weeks 
using GfCSF at a dose of 10 mcg/kg every 12 hours for 
five days. On day five, the WBC count was 36.2×106/
mL and the absolute circulating CD34+ was 7.2 cells 
per µL, so the collection was aborted again. Three 
months later plerixafor had become available at our cenf
ter for compassionate use and the patient consented to 
receive the medication so GfCSF was started at 10 µg/
kg in the morning for four days followed on day four by 
plerixafor at 0.24 mg/kg subcutaneously in the evening, 
approximately 11 hours prior to initiation of apheresis. 
Following plerixafor administration, the WBC count 
was 34.5×1086/mL, and CD34 reached 17.3 cells per 
µL, so we collected 4.22×106/kg CD34+ cells in the 
first session. Following to this, we decided to give our paf
tient another dose of plerixafor and the yield of CD34+ 
cells this time was 1.52×106/kg, so the total collected 
cells were 5.74×106/kg. The collection procedure went 
smoothly and the patient complained only of mild nauf
sea and gastrointestinal discomfort. For the HSCT 
part, the plan was to give our patient two consecutive 
courses of highfdose chemotherapy, each followed by an 
infusion of autologous PBSCs so he received highfdose 
chemotherapy of carboplatin 750 mg/m2 plus etoposide 
700 mg/m2 for three days followed by stem cell infusion. 
The patient engrafted on day +11 with complete platef
let recovery on day +28. Upon follow up around day 
+60, the patient was found to have disease progression. 
Consequently, he was referred to his primary oncologist 
for palliative chemotherapy. 
DISCUSSION
Highfdose chemotherapy with HSCT is an accepted 
secondf or thirdfline salvage approach to treat patients 
with metastatic germ cell tumors. Two consecutive 
courses of highfdose chemotherapy consisting of carbof
platin and etoposide, each followed by an infusion of auf
tologous PBSCs can achieve 70% diseaseffree survival.4 
The success of this approach depends on the collection 
of adequate number of PBSCs. To achieve this, transf
plantation teams have attempted several strategies, inf
cluding the use of colony stimulating factors alone or in 
combination with chemotherapy. Adding chemotherapy 
to growth factor enhances mobilization but at the exf
pense of increased cost and toxicity.10,11 Nevertheless, 
a significant proportion of patients fail to collect the 
desired number of CD34+ cells due to factors such as 
age, sex, diagnosis, prior radiotherapy or chemotherapy 
regimens, cumulative alkylator dose, prefcollection inf
fections, and time from last chemotherapy.10,11 Our paf
tient was heavily pretreated with several courses of chef
motherapy and failed to mobilize despite continued and 
escalated dosing of GfCSF.
Plerixafor is the first in a new class of agents that 
reversibly inhibits the binding of stromal cellfderived 
factor 1 (SDFf1) to its receptor CXC chemokine recepf
tor 4 (CXCR4) resulting in the mobilization of highly 
functional PBSCs into the circulation.5 In clinical trials, 
plerixafor, in combination with GfCSF, increased the 
number of patients achieving both the minimum and 
target stem cell levels in fewer apheresis sessions.8,9 In 
addition, this agent demonstrated an excellent safety 
profile with mildftofmoderate side effects reported from 
the clinical studies, mainly gastrointestinal disorders 
and injection site reactions.8,9 Adding plerixafor to Gf
CSF resulted in a significant increase in the collected 
cells from our patient and with only two sessions of 
apheresis, the collected cells were adequate to conduct 
two transplants. Furthermore, our patient reported only 
mild gastrointestinal disorders and did not complain of 
any severe adverse event while taking plerixafor. We have 
used plerixafor to mobilize our lymphoma and MM paf
tients under the compassionate use program and after 
its approval by the FDA. The application of plerixafor 
in patients with solid tumors is an offflabel use of this 
medication. Nevertheless, we chose to offer plerixafor to 
our patient under the compassionate use program since 
we had no alternatives. To the best of our our knowledge 
this is the first published report of plerixafor use in mof
bilizing patients with solid tumors. 
Finally, it is worth mentioning that one major conf
cern with the use of plerixafor is its high cost (approxif
mately $7000 for a singlefuse vial). However, taking into 
consideration that the high failure rates of mobilization 
can adversely affect patient outcomes and negatively imf
pact resource utilization in terms of higher doses of Gf
CSF and repeated apheresis sessions, it seems essential 
to develop guidelines and tools to help institutions make 
the most costfeffective use of this novel medication.12
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